Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Intellipharmaceutics International Inc V.IPCI.H

Alternate Symbol(s):  IPCIF

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several... see more

TSXV:IPCI.H - Post Discussion

Intellipharmaceutics International Inc > Anson Funds Invests in IPCI
View:
Post by archeo753 on Mar 20, 2018 4:59pm

Anson Funds Invests in IPCI

Short seller who helped put Nobilis (HLTH) through a world of hurt a couple of years ago (which it still hasn't recoverd from) has decided to go long on IPCI.  Could they have been behind some of the share manipulation happening with IPCI over the last while and finally got the share price down to a level where the potental profits compelled them to go long?  I will take this to be a bullish sign.  Sad.
----------------------------
SCHEDULE 13G 
This Schedule 13G (this “Schedule 13G”) is being filed on behalf of Anson Funds Management LP (d/b/a Anson Group), a Texas 
limited partnership, Anson Management GP LLC, a Texas limited liability company, Mr. Bruce R. Winson, the principal of Anson Funds 
Management LP and Anson Management GP LLC, Anson Advisors Inc. (d/b/a Anson Funds), an Ontario, Canada corporation, Mr. Amin 
Nathoo, a director of Anson Advisors Inc., and Mr. Moez Kassam, a director of Anson Advisors Inc., relating to Common shares, no par 
value (the “Common Stock”), of Intellipharmaceutics International Inc., a Canadian corporation (the “Issuer”). 
This Schedule 13G relates to Common Stock of the Issuer purchased by a private fund to which Anson Funds Management LP and 
Anson Advisors Inc. serve as co-investment advisors (the “Fund”). Anson Funds Management LP and Anson Advisors Inc. serve as 
co-investment advisors to the Fund and may direct the vote and disposition of the 2,916,666 shares of Common Stock held by the Fund. As 
the general partner of Anson Funds Management LP, Anson Management GP LLC may direct the vote and disposition of the 2,916,666 
shares of Common Stock held by the Fund. As the principal of Anson Fund Management LP and Anson Management GP LLC, 
Mr. Winson may direct the vote and disposition of the 2,916,666 shares of Common Stock held by the Fund. As directors of Anson 
Advisors Inc., Mr. Nathoo and Mr. Kassam may each direct the vote and disposition of the 2,916,666 shares of Common Stock held by the 
Fund.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities